How targeting a rare blood cancer complication, or bacteria in colorectal cancer bolster immunotherapy outcomes? – CRI

Cancer Research Institute (CRI) shared on LinkedIn:

“How could targeting a rare blood cancer complication, or bacteria in colorectal cancer bolster immunotherapy outcomes?

CRI Clinical Innovator Dr. Julio Delgado of Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and CRI Postdoctoral Fellow Dr. Jorge Luis Galeano Niño of The University of Texas at El Paso share their insights in our newest blog, during National Hispanic Heritage Month.”

More posts featuring Cancer Research Institute on oncodaily.com